A practical reference on Anti-doping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-17 and is reviewed periodically as new material appears.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport; not approved as medicine | Listed by WADA at all times. |
| Common synonyms | GW501516, GW-501516, endurobol | Cardarine is a colloquial name. |
| Typical analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Common test matrix | Urine | Blood and dried blood spots also possible. |
| Legal classification | Varies by country | Often treated as unapproved drug or research chemical. |
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
==== Study techniques ==== Much of what is known about cellular morphology changes and the effects of Rho proteins comes from the creation of a constitutively active mutated form of the protein. Mutation of a key amino acid can alter the conformation of the entire protein, causing it to permanently adopt a conformation that resembles the GTP-bound state. This protein cannot be inactivated normally, through GTP hydrolysis, and is thus "stuck on". When a Rho protein activated in this manner is expressed in 3T3 cells, morphological changes such as contractions and filopodia formation ensue. Because Rho proteins are G-proteins and plasma membrane bound, their location can be easily controlled. In each situation, whether it be wound healing, cytokinesis, or budding, the location of the Rho activation can be imaged and identified. For example, if a circular hole is inflicted in a spherical cell, Cdc42 and other active Rhos are seen in highest concentration around the circumference of the circular injury. One method of maintaining the spatial zones of activation is through anchoring to the actin cytoskeleton, keeping the membrane-bound protein from diffusing away from the region where it is most needed. Another method of maintenance is through the formation of a large complex that is resistant to diffusion and more rigidly bound to the membrane than the Rho itself.
=== Presence in livestock species during gestation === Bovine/Ovine RBP, identical to that found in plasma has been identified in the placental tissues of both the ovine and the bovine, suggesting that RBP may be highly involved in retinol transport and metabolism during pregnancy. However, exact timing of expression had been yet to be identified. An antiserum specific for bovine conceptus RBP and immunohistochemistry has been utilized to identify the presence of RBP at different stages of early pregnancy. Strong immunostaining and hybridization were observed in the trophectoderm of tubular, but not spherical blastocysts at day 13. RBP mRNA was localized to epithelial cells of the chorion, allantois, and amnion at day 45 of pregnancy. Lastly, RBP mRNA was detected in the cotyledons, the fetal contribution to the placenta and the site of attachment to the uterine epithelium for fetal/maternal exchange. Expression of RBP in developing conceptuses, extraembryonic membranes, and at the fetal-maternal interface indicate that there may be some regulation of retinol transport and metabolism that occurs due to RBP by the extraembryonic membranes. Within the uterus of pregnant bovines, it has been found that RBP synthesis in the luminal and glandular epithelium is quite similar to that of a cyclic animal's; however upon reaching day 17 of the estrous cycle, levels of RBP remain constant and continue to gradually rise throughout gestation. It has also been suggested that ovarian steroids may play a role in regulating uterine RBP expression.
=== San Antonio Nathan Shock Center === The San Antonio Nathan Shock Center (NSC) is one of only eight National Institute on Aging (NIA)-funded Nathan Shock Centers of Excellence in the Basic Biology of Aging in the United States. Since its establishment in 1995, the Center has served as an internationally recognized resource dedicated to advancing the fundamental biology of aging and accelerating the development of interventions that promote healthy aging and extend healthspan. The overarching mission of the Center is to identify the molecular, cellular, and physiological mechanisms that drive the aging process and translate these discoveries into strategies that delay or prevent age-associated diseases and functional decline. The San Antonio Nathan Shock Center provides investigators with an integrated, "one-stop-shop" research infrastructure that supports every stage of aging research—from experimental design and animal model development to functional phenotyping, pathology, metabolism, pharmacology, and data interpretation. This comprehensive approach enables investigators to conduct rigorous, multidisciplinary studies that examine lifespan, healthspan, and the biological mechanisms underlying aging. By integrating specialized expertise and state-of-the-art technologies within a single research environment, the Center accelerates scientific discovery while promoting collaboration among investigators locally, nationally, and internationally. The Center is organized around six highly integrated research cores that provide specialized services and scientific expertise.
Sources: en.wikipedia.org
After he married the widow of Christian Herter in 1916, he worked in his private laboratory in Scarsdale, New York and had several close collaborations with other scientists. His main working fields were amino acids and enzymes. The extraction of amino acids from hydrolyzed peptides by butanol was invented by him. He also was interested in organic chemistry and synthesis, and devised the Dakin reaction and the Dakin–West reaction. He died shortly after the death of his wife in early 1952.
== Occurrences == Homoarginine is a growth inhibitor of Staphylococcus aureus, Escherichia Coli and Candida albicans, indicating it inhibits particular microbial growth and germination pathways. Homoarginine is assumed to be an antimetabolite of arginine. Many studies have shown that it acts as a competitive inhibitor in most cases, but there are also controversial studies showing that it is also an organ specific, non-competitive inhibitor as well. Studies have also shown that it is toxic when targeting Insecta and Rattus norvegicus. In its inhibition, is also often found in occurrences with the lungs, cervix, testis and is an inhibitor of bone and liver-specific alkaline phosphatase enzymes. This amino acid derivative is also found in occurrence with murine osteosarcoma cell proliferation. Levels of homoarginine have been found to increase during pregnancy, but more studies are underway to confirm this thoroughly.
== 90Sr contamination in the environment == 90Sr is not quite as likely as 137Cs to be released as a part of a nuclear reactor accident because it is much less volatile, but is probably the most dangerous component of the radioactive fallout from a nuclear weapon. A study of hundreds of thousands of deciduous teeth, collected by Dr.Louise Reiss and her colleagues as part of the Baby Tooth Survey, found a large increase in 90Sr levels through the 1950s and early 1960s. The study's final results showed that children born in St. Louis, Missouri, in 1963 had levels of 90Sr in their deciduous teeth that was 50 times higher than that found in children born in 1950, before the advent of large-scale atomic testing. Reviewers of the study predicted that the fallout would cause increased incidence of disease in those who absorbed 90Sr into their bones. However, no follow up studies of the subjects have been performed, so the claim is untested. An article with the study's initial findings was circulated to U.S. President John F. Kennedy in 1961, and helped convince him to sign the Partial Nuclear Test Ban Treaty with the United Kingdom and Soviet Union, ending the above-ground nuclear weapons testing that placed the greatest amounts of nuclear fallout into the atmosphere. The Chernobyl disaster released roughly 10 PBq, or about 5% of the core inventory, of 90Sr into the environment. The Kyshtym disaster released 90Sr and other radioactive material into the environment. It is estimated to have released 20 MCi (800 PBq) of radioactivity.
Sources: en.wikipedia.org
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.
Laboratories use liquid chromatography-tandem mass spectrometry to detect GW501516 and its metabolites. Urine is commonly tested, and testing can occur in and out of competition.
No, cardarine is not a SARM. It is a PPARδ agonist, which acts on a different receptor. The two classes are often confused in online discussions.
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.